Previous 10 | Next 10 |
2024-05-02 16:07:53 ET More on Soleno Therapeutics Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch Soleno Therapeutics GAAP EPS of -$0.33 misses by $0.07 Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings...
REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results from the Company...
2024-04-29 16:02:16 ET Summary Soleno Therapeutics, Inc.'s New Drug Application filing of DCCR for the treatment of patients with Prader-Willi Syndrome expected by mid-2024. Ability to file NDA of DCCR for PWS was because of statistical significance achieved based on the primary e...
Soleno Therapeutics, Inc. (NASDAQ: SLNO) is one of today's top gainers. The company's shares have moved 34.88% on the day to $51.1. Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of...
2024-04-29 11:11:00 ET Shares of Soleno Therapeutics (NASDAQ: SLNO) were skyrocketing 39.8% higher as of 10:51 a.m. ET on Monday. The huge gain came after the clinical-stage biopharmaceutical company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy ...
2024-04-29 10:02:54 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
A look at the top 10 most actives in the United States SoFi Technologies Inc. (SOFI) fell 9.7% to $7.1068 on volume of 45,729,887 shares Tesla Inc. (TSLA) rose 11.6% to $187.7701 on volume of 45,057,076 shares Collective Audience Inc. (CAUD) rose 71.6% to $0.669199 on volume of 34,955,653...
2024-04-29 08:29:50 ET More on Soleno Therapeutics Soleno Therapeutics GAAP EPS of -$0.33 misses by $0.07 Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings data for Soleno Therapeutics Financial information for Soleno Therapeutics...
First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 REDWOOD CITY, Calif., April 29, 2024 (GLOBE NEW...
2024-03-07 10:01:04 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
News, Short Squeeze, Breakout and More Instantly...
Soleno Therapeutics Inc. Company Name:
SLNO Stock Symbol:
NASDAQ Market:
Soleno Therapeutics Inc. Website:
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to...
2024-06-24 16:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3...